November 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
February 2026 in “MedBA Medicine” Erlotinib can cause unexpected side effects like eyelash growth and scarring.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
August 2011 in “Reactions Weekly” A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.
46 citations
,
October 2022 in “Biomaterials” 68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
April 2026 in “Frontiers in Pharmacology” Erzhi Pill shows promise for health issues but needs better quality control and clearer usage guidelines.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
8 citations
,
June 2024 in “Pharmaceutics” PEA-ENL improves skin delivery and reduces inflammation without side effects.
9 citations
,
July 2022 in “EMBO molecular medicine” Blocking certain immune signals can reduce skin damage from radiation therapy.
25 citations
,
February 2024 in “Biomaterials” Stem cell-derived organoids can improve skin healing.
4 citations
,
August 2023 in “Varna Medical Forum” TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
May 2025 in “REVISTA DA ASSOCIAÇÂO DE FARMÁCIAS VIVAS” The serum is effective, safe, and stable for skincare.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
6 citations
,
February 2024 in “Pharmaceutics” ELIP-based CRISPR delivery improves heart disease gene editing but needs more testing.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology”
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
March 2009 in “Dermatology Online Journal” Manipulating EGFR signaling may help treat hair loss and promote hair growth.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
198 citations
,
May 2021 in “Advanced Materials” Triboelectric nanogenerators can use body movement to power therapeutic treatments, potentially transforming personalized healthcare.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.